The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain



Status:Completed
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - 65
Updated:5/16/2018
Start Date:January 2014
End Date:April 1, 2017

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
This study will test whether treatment with N-acetyl-L-cysteine (NAC) is safe and decreases
pain in patients with chronic neuropathic pain. The investigators hypothesize that NAC will
be a useful adjunct to opioid treatment in chronic neuropathic pain.

This is an open-label study to evaluate the safety and efficacy of N-acetyl-L-cysteine in
patients with Chronic neuropathic pain.

Inclusion Criteria:

- 18-65 years old

- non-cancer neuropathic pain

- stable dose of opioids for pain

- using breakthrough pain meds

- still with persistent pain per VAS

Exclusion Criteria:

- pregnant or nursing

- serious medical or psychiatric illness (including uncontrolled hypertension)

- active stomach ulcer, history or seizures or asthma

- breakthrough pain meds other than opioids

- using illicit drugs
We found this trial at
1
site
Virginia Commonwealth University
Richmond, Virginia 23298
(804) 828-0100
Principal Investigator: Dace S Svikis, PhD
Phone: 804-827-1519
Virginia Commonwealth University Since our founding as a medical school in 1838, Virginia Commonwealth University...
?
mi
from
Richmond, VA
Click here to add this to my saved trials